Clinical Research in Southampton
Southampton Children's Hospital

A A A Text only | Accessibility | Privacy and cookies

Home
About the Trust
Our services
Patients and visitors
Our hospitals
Education
Research
Working here
Contact us

Browse site A to Z

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Search results

Go To Simple Search

Search Type: Criteria:

You could also try: gap (135), time (1000), period (558), space (242), distance (88)

Asciminib

Description: Chemotherapy Protocol Chronic Myeloid Leukaemia Asciminib Regimen • Asciminib Indication • Patients with chronic phase Philadelphi
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/CML/Asciminib.pdf

Osimertinib

Description: Chemotherapy Protocol Lung cancer - Non-small cell (NSCLC) OSIMERTINIB Regimen • NSCLC - Osimertinib Indication • Osimertinib i
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/Osimertinib.pdf

BEACON protocol v8.0 07Mar2023 signed

Description: A randomised phase IIb trial of BE AC v izumab added to Temozolomide O ± Irin tecan for children with N refractory
Url: /Media/UHS-website-2019/Docs/PaediatricOncology/beacon-protocol-v8.0-07mar2023-signed.pdf

InP RIVAC (66) cytarabine etoposide ifosfamide rituximab

Description: Chemotherapy Protocol LYMPHOMA CYTARABINE-ETOPOSIDE-IFOSFAMIDE-RITUXIMAB (RIVAC) 66 years and above Inpatient Regimen There are multiple versions of this protocol
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/InP-RIVAC-66-cytarabine-etoposide-ifosfamide-rituximab.pdf

InP RIVAC (65) cytarabine etoposide ifosfamide rituximab

Description: Chemotherapy Protocol LYMPHOMA CYTARABINE-ETOPOSIDE-IFOSFAMIDE-RITUXIMAB (RIVAC) 65 years and below Inpatient Regimen There are multiple versions of this protocol
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/InP-RIVAC-65-cytarabine-etoposide-ifosfamide-rituximab.pdf

STHW869 Antibiotic Guideline Ranges 2021 - 2022

Description: Antimicrobial Reference Laboratory GUIDELINE RANGES FOR TDM 2021 - 2022 Alan Noel Antimicrobial Reference Laboratory North Bristol NHS Trust Southmea
Url: /Media/SUHTExtranet/DepartmentOfInfection/STHW869-Antibiotic-Guideline-Ranges-2021-2022.pdf

DH IVIg approved indications full guidance July 2011

Description: DH INFORMATION READER BOX Policy HR / Workforce Management Planning / Clinical Performance Document Purpose Gateway Reference Title Author Publicatio
Url: /Media/SUHTExtranet/TrustMedicinesFormulary/Forms/DH-IVIg-approved-indications-Full-Guidance-July-2011.pdf

CladribineSC

Description: Chemotherapy Protocol HAIRY CELL LEUKEMIA CLADRIBINE (SC) Regimen • HCL – Cladribine (SC) Indication • Hairy cell leukemia Toxicity Drug Cladribine Adverse Effect Skin
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/HCL/CladribineSC.pdf

Gilteritinib

Description: Chemotherapy Protocol Acute Myeloid Leukaemia GILTERITINIB Regimen  AML - Gilteritinib Indication Gilteritinib for treating relapsed/refractory FLT3 mutation posi
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/AML/Gilteritinib.pdf

InP-MATRix

Description: Chemotherapy Protocol LYMPHOMA MATRix – CYTARABINE-METHOTREXATE-RITUXIMAB-THIOTEPA Inpatient Regimen Regimen • Lymphoma – InP-MATRix – Cytarabine-Methotrexate-Rituximab-Thiotepa Indication • Non-Hodgkin
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/InP-MATRix.pdf

11 to 20 of 210

Previous 1 2 3 4 5 … Next